1
|
Li Z, Yue Q, Chen Y, Zhang Y, Wan Y. Quantitative Assessment of Pancreatic Fat by Quantitative CT in Type 2 Diabetes Mellitus. Int J Gen Med 2022; 15:7977-7984. [PMID: 36337672 PMCID: PMC9629247 DOI: 10.2147/ijgm.s383783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2022] [Accepted: 10/17/2022] [Indexed: 11/07/2022] Open
Abstract
Objective To characterize the pancreatic fat deposition (PFD) in patients with type 2 diabetes mellitus (T2DM) by quantitative computed tomography (QCT) and investigate the relationship between PFD and clinical metabolic parameters and islet function. Materials and Methods A total of 150 patients with T2DM and 93 age-matched healthy subjects underwent QCT to quantify PFD were included. PFD and various biochemical parameters were correlated by statistical methods and multiple stepwise linear regression modeling. Results PFD measured by QCT in the T2DM group was statistically higher than that in the healthy control group, and the pancreatic CT value was statistically lower than that in the control group. The QCT measured PFD was negatively correlated with the pancreatic CT values (P < 0.001), and positively correlated with triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), visceral fat area (VAT) and insulin resistance index (HOMA-IR) (P < 0.05) in the T2DM patients. Multiple stepwise linear regression analysis identified PFD as the dependent variable factor for T2DM. Conclusion This study suggests QCT as a reliable technique in measuring PFD in T2DM. High PFD is positively correlated with the degree of insulin resistance and may play an important role in islet cell dysfunction in T2DM.
Collapse
Affiliation(s)
- Zhizhen Li
- Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China
| | - Qingmei Yue
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China
| | - Yunjin Chen
- Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China
| | - Yifan Zhang
- Department of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China
| | - Yamin Wan
- Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China
- Correspondence: Yamin Wan, Email
| |
Collapse
|
2
|
Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res 2020; 159:104984. [PMID: 32502637 DOI: 10.1016/j.phrs.2020.104984] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 04/27/2020] [Accepted: 05/29/2020] [Indexed: 02/07/2023]
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) in the general population is estimated at 25 %, and there is currently no effective treatment of NAFLD. Although insulin resistance (IR) is not the only factor causing the pathogenesis of NAFLD, hepatic IR has a cause-effective relationship with NAFLD. Improving hepatic IR is a potential therapeutic strategy to treat NAFLD. This review highlights the molecular mechanisms of hepatic IR in the development of NAFLD. Available data on potential drugs including glucagon-like peptide 1 receptor (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR-γ/α/δ) agonists, farnesoid X receptor (FXR) agonists, etc. are carefully discussed.
Collapse
|
3
|
Li Z, Liu C, Zhou Z, Hu L, Deng L, Ren Q, Qian H. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice. Pharmacol Res 2020; 153:104679. [DOI: 10.1016/j.phrs.2020.104679] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 11/20/2019] [Accepted: 01/30/2020] [Indexed: 12/12/2022]
|
4
|
de-Lima-Júnior JC, Rodovalho S, Van de Sande-Lee S, Monfort-Pires M, Rachid B, Cintra RM, Ramos CD, Cendes F, Folli F, Velloso LA. Effect of pioglitazone treatment on brown adipose tissue volume and activity and hypothalamic gliosis in patients with type 2 diabetes mellitus: a proof-of-concept study. Acta Diabetol 2019; 56:1333-1339. [PMID: 31506721 DOI: 10.1007/s00592-019-01418-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 08/29/2019] [Indexed: 02/06/2023]
Abstract
AIMS This study aimed to evaluate the effect of pioglitazone on brown adipose tissue function and hypothalamic gliosis in humans. Brown adipose tissue and the hypothalamus are regarded as important potential pharmacological targets to metabolic diseases, and defining the impact of current therapies on their structure and/or function could provide therapeutic advance in this field. METHODS Six patients with type 2 diabetes were treated for 24 weeks with pioglitazone 30 mg/day as an add-on therapy. Brown adipose tissue glucose uptake and volume were determined using 18F-FDG PET/CT scans; hypothalamic gliosis was determined using MRI scans; blood was collected for hormone and biochemistry measurements. All tests were performed at inclusion and six months after pioglitazone introduction. RESULTS Pioglitazone treatment led to a significant 3% body mass increase. There were neither changes in cold-induced brown adipose tissue glucose uptake and volume nor changes in hypothalamic gliosis. CONCLUSIONS This is a proof-of-concept study that provides clinical evidence for a lack of action of a thiazolidinedione, pioglitazone, to promote homogeneous and measurable changes in brown adipose tissue volume and also in hypothalamic gliosis after 6 months of treatment.
Collapse
Affiliation(s)
- José C de-Lima-Júnior
- Laboratory of Cell Signaling, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil
| | - Sylka Rodovalho
- Laboratory of Cell Signaling, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil
| | - Simone Van de Sande-Lee
- Laboratory of Cell Signaling, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
- Department of Internal Medicine, Federal University of Santa Catarina (UFSC), Florianópolis, SC, Brazil
| | - Milena Monfort-Pires
- Laboratory of Cell Signaling, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil
| | - Briana Rachid
- Laboratory of Cell Signaling, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil
| | - Riobaldo M Cintra
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil
| | - Celso D Ramos
- Department of Radiology, University of Campinas, Campinas, São Paulo, 13084-970, Brazil
| | - Fernando Cendes
- Neuroimaging Laboratory, Department of Neurology, University of Campinas, Campinas, Brazil
| | - Franco Folli
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil
- School of Medicine, Endocrinology and Metabolism Dipartimento di Scienze Della Salute, Universita' degli Studi di Milano, Milan, Italy
- Departmental Unit of Diabetes and Metabolic Disorders, Azienda Socio-Sanitaria Santi Paolo e Carlo, Via A. Di Rudini, 8, 20143, Milan, Italy
| | - Lício A Velloso
- Laboratory of Cell Signaling, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
- Obesity and Comorbidities Research Center, Campinas, São Paulo, Brazil.
| |
Collapse
|